Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tetrahydrocannabinol + myrcene + beta-caryophyllene
- Development stage
- Unknown
- Lead developer
- University of California, Los Angeles
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
This research compound is a combination of the phytocannabinoid tetrahydrocannabinol (THC) and the terpenes myrcene and beta-caryophyllene, currently under investigation by the UCLA Cannabis Research Initiative. Led by Dr. Ziva Cooper, the study explores the entourage effect, specifically whether these terpenes can enhance the analgesic properties of THC while potentially mitigating its adverse effects. THC primarily acts as a partial agonist at the CB1 and CB2 cannabinoid receptors. Beta-caryophyllene is a sesquiterpene that functions as a selective CB2 receptor agonist, while myrcene is a monoterpene hypothesized to interact with CB1 receptors and TRPV1 channels. The combination is being evaluated in a Phase 1 clinical trial for pain management using vaporized administration.
- Other names
- THC + myrcene + beta-caryophylleneTHC-terpene combination
02
Targets
CNR1 (Cannabinoid receptor 1)TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on tetrahydrocannabinol + myrcene + beta-caryophyllene.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tetrahydrocannabinol + myrcene + beta-caryophyllene.